About Oncologica
Oncologica is a company based in Saffron Walden (United Kingdom) founded in 2003 by Marco Loddo and Gareth Haydn Williams. Oncologica has raised $976.12 thousand across 1 funding round. The company has 272 employees as of December 31, 2021. Oncologica offers products and services including Oncofocus, ProstateFocus, and Genomic Research Services. Oncologica operates in a competitive market with competitors including Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
- Headquarter Saffron Walden, United Kingdom
- Employees 272 as on 31 Dec, 2021
- Founders Marco Loddo, Gareth Haydn Williams
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Oncologica Uk Limited
- Date of Incorporation 11 Nov, 2014
- Jurisdiction CAMBRIDGE, ENGLAND
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$976.12 K (USD)
in 1 rounds
-
Latest Funding Round
$976.12 K (USD), Seed
Oct 26, 2020
-
Investors
Not available
-
Employee Count
272
as on Dec 31, 2021
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Oncologica
Oncologica offers a comprehensive portfolio of products and services, including Oncofocus, ProstateFocus, and Genomic Research Services.
Matches tumor genetics with targeted therapies for personalized cancer treatment.
Non-invasive urine test for early prostate cancer detection.
Provides high-quality genetic testing and bioinformatics solutions.
Funding Insights of Oncologica
Oncologica has successfully raised a total of $976.12K through 1 strategic funding round. The most recent funding activity was a Seed round of $976.12 thousand completed in October 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investments & Acquisitions by Oncologica
Investment portfolio details for Oncologica
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Oncologica
Detailed financials for Oncologica
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Oncologica Comparisons
Peer comparison for Oncologica
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Oncologica
Oncologica operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Denali Therapeutics, MiRagen, Poseida Therapeutics, Juno Therapeutics and Castle Biosciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Neurodegenerative disease therapies are developed for Alzheimer's, ALS, and Parkinson's.
|
|
| Locked | Locked | Locked |
MicroRNA-based therapeutics are developed for treating multiple diseases.
|
|
| Locked | Locked | Locked |
Developer of gene therapies for treating cancer and liver orphan disease by using gene editing technologies
|
|
| Locked | Locked | Locked |
CAR T-cell and T-cell receptor immunotherapies for cancer are developed.
|
|
| Locked | Locked | Locked |
Precision diagnostic and prognostic tests are developed by Castle Biosciences.
|
|
| Locked | Locked | Locked |
Genomic sequencing and diagnosis software is provided for healthcare.
|
Detailed competitors of Oncologica
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Oncologica
Complete news archive for Oncologica
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Oncologica
Oncologica was founded in 2003 and raised its 1st funding round 17 years after it was founded.
Oncologica is headquartered in Saffron Walden, United Kingdom. It is registered at Saffron Walden, Essex, United Kingdom.
Oncologica is a funded company, having raised a total of $976.12K across 1 funding round to date.
As of Dec 31, 2021, the latest employee count at Oncologica is 272.
Oncologica was founded in 2003 in Saffron Walden, United Kingdom, within the biotechnology sector focused on oncology. Genomic profiling tests for precision medicine are provided by the company, alongside the Immunofocus IHC assay, which delivers tumor scores to predict therapy responses. Operations center on DNA analysis to support targeted cancer treatments, with activities based in the UK.
Oncologica's top competitors include Juno Therapeutics, Personalis and Poseida Therapeutics.
Oncologica offers Oncofocus, ProstateFocus, and Genomic Research Services.